Repertoire Immune Medicines and Eli Lilly Announce Collaboration
Repertoire Immune Medicines is excited to announce a significant strategic collaboration with Eli Lilly and Company, focusing on the development of tolerizing therapies to treat various autoimmune diseases. This partnership is set to leverage Repertoire's advanced DECODE™ platform, designed to pioneer T cell-targeted immune medicines, along with Lilly’s strong commitment to delivering transformative care to patients suffering from unmet medical needs.
The Vision Behind the Collaboration
The collaboration aims to cultivate innovative treatment options that can restore immune homeostasis and facilitate long-lasting remission for patients without leading to the overall immune suppression often associated with existing therapies.
Under this agreement, Repertoire will spearhead the collaboration through initial discovery phases and until development candidates are nominated, after which Lilly will manage clinical development, regulatory affairs, manufacturing, and ultimately the commercialization of the identified candidates.
Utilizing Innovative Platforms for Therapy Development
Repertoire's proprietary DECODE™ technology is a ground-breaking platform that enhances the discovery process for tolerizing therapies. It focuses on identifying T cell receptor (TCR) and epitope interactions that may serve as a foundation for creating effective treatments for autoimmune disorders.
Dr. Torben Straight Nissen, Chairman and CEO of Repertoire, highlighted the strategic importance of this partnership, stating that it extends their pipeline of tolerant therapies. He expressed optimism about how this collaboration could lead to novel medicines that reset immune dysfunctions and promote overall health.
Financial Framework of the Collaboration
As part of the collaboration terms, Repertoire will receive an initial payment of $85 million, with the potential to achieve up to $1.84 billion contingent upon meeting specified development and commercialization milestones. Additionally, tiered royalties on net sales are included, creating a robust financial incentive for both parties.
About Repertoire Immune Medicines
Repertoire Immune Medicines is at the forefront of biotechnology, with a mission to decode the immune system's intricate functioning to better understand how immunity can be harnessed against disease. Their DECODE™ platform delivers a holistic view of immune interactions, facilitating the development of potentially revolutionary T cell-focused therapies for cancer and autoimmune diseases.
Founded in 2019 by Flagship Pioneering, Repertoire has established operational hubs in Cambridge and Zurich. The company is dedicated to translating immune insights into therapies through collaboration with renowned industry leaders, including Bristol Myers Squibb and Pfizer.
Frequently Asked Questions
What is the primary goal of the collaboration between Repertoire and Lilly?
The collaboration focuses on developing tolerizing therapies for autoimmune diseases, aiming to restore immune balance without causing widespread immune suppression.
What platform is Repertoire using in this partnership?
Repertoire is utilizing its DECODE™ platform to discover and develop new treatment candidates targeting T cell responses.
What financial terms were included in the agreement?
Repertoire will receive an upfront payment of $85 million, with additional potential earnings up to $1.84 billion based on development milestones, plus tiered royalties.
How does this collaboration fit into Repertoire's overall mission?
This collaboration expands Repertoire's pipeline of innovative therapies and aligns with their goal of addressing immunological health through targeted treatments.
What kind of therapies are expected as outcomes of this collaboration?
The therapies developed are anticipated to address the root causes of autoimmune diseases by resetting the immune system to a healthier state.
